Dose adjustment based on the plasma level measurement used anti-FXa chromogenic assay on the use of non-vitamin K antagonist oral anticoagulants (NOACs) improved the overall benefit of NOACs dosing in patients with atrial fibrillation: Authors' reply

Affiliations

¹ Division of Electrophysiology and Cardiac Devices, Department of Cardiology, University Hospital Zurich, Rämistrasse 100, CH-8091 Zurich, Switzerland.
² Department of Cardiovascular Research Antwerp University, and of Cardiology University Hospital Antwerp, Antwerp, Belgium.

Comment

Jan Steffel et al. Europace. 2021.

. 2021 Oct 9;23(10):1686-1687.

doi: 10.1093/europace/euab220.

¹ Division of Electrophysiology and Cardiac Devices, Department of Cardiology, University Hospital Zurich, Rämistrasse 100, CH-8091 Zurich, Switzerland.
² Department of Cardiovascular Research Antwerp University, and of Cardiology University Hospital Antwerp, Antwerp, Belgium.

No abstract available

Comment on

2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation.
Steffel J, Collins R, Antz M, Cornu P, Desteghe L, Haeusler KG, Oldgren J, Reinecke H, Roldan-Schilling V, Rowell N, Sinnaeve P, Vanassche T, Potpara T, Camm AJ, Heidbüchel H; External reviewers. Steffel J, et al. Europace. 2021 Oct 9;23(10):1612-1676. doi: 10.1093/europace/euab065. Europace. 2021. PMID: 33895845 Free PMC article. No abstract available.
Dose adjustment based on the plasma level measurement used anti-FXa chromogenic assay on the use of non-vitamin K antagonist oral anticoagulants (NOACs) improved the overall benefit of NOACs dosing in patients with atrial fibrillation.
Suwa M, Morii I, Kino M. Suwa M, et al. Europace. 2021 Oct 9;23(10):1686. doi: 10.1093/europace/euab219. Europace. 2021. PMID: 34549782 No abstract available.